Skip to main content

Dan Vogl, MD

Dan Vogl, MD, University of Pennsylvania
Conference Coverage
01/23/2024
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma,...
01/23/2024
Lymphoma, Leukemia & Myeloma Network